Evidence mapPaperPMID 41828342Full record

ReviewInternational journal of molecular sciences2026

Applications of Metabolomics to the Clinical Management of Breast Cancer: New Perspectives for Diagnosis, Treatment and Prognosis.

Yuqiu Li, Hongnan Mo

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yuqiu LiDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China.
Hongnan MoDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China.ORCID 0000-0002-2887-7985

Funding

National Natural Science Foundation of China 82573485National Science and Technology Major Project 2025ZD0543900
6 · The paper itself

Abstract

Breast cancer is a heterogeneous malignancy that often changes during diagnosis and treatment, so timely monitoring of tumors, patients and treatment responses is crucial to improve the prognosis of patients. With the development of precision oncology, early patient stratification and the formulation of tailored therapeutic approaches have become essential strategies to maximize treatment efficacy. Several techniques, such as molecular pathology and genomics analysis have been thoroughly studied in the diagnosis and treatment of breast cancer, but they only evaluate and analyze from the perspective of patients or tumors in isolation. Metabolomics uses high-throughput analytical techniques to provide a functional readout of the biological phenotype, reflecting the sum of alterations occurring at the DNA, RNA, and protein levels. Therefore, through the detection of tumor tissues and peripheral blood of patients, metabolomics could describe the bidirectional interaction between the tumor and its microenvironment, as well as the systemic metabolic changes in patients to evaluate cancer progression from both tumor and patient aspects in a more comprehensive way. In this review, we summarize the currently available techniques for metabolomics and how metabolomics can be used to improve the clinical management of breast cancer patients, including diagnosis, treatment, and prognosis. We also discuss current challenges and future directions in metabolomics research.

Indexed as

Biomarkers, TumorBreast NeoplasmsMetabolomicsFemaleHumansMetabolomePrecision MedicinePrognosisBiomarkers, Tumorbreast cancermetabolic featuresmetabolomicsprecision medicine

Identifiers

PMID41828342
PMCPMC12984177

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.